Genetic Testing: New Medicare Early NGS Cancer Test Coverage Policy Is Less than Meets the Eye

by Glenn S. Demby | Jan 3, 2020 | Essential, Laboratory Industry Report, Reimbursement-lir

For Myriad Genetics, Foundation Medicine and other manufacturers of next-generation sequencing (NGS)-based test panels for early-stage cancer risk assessment, the recent announcement of CMS’ decision to provide limited Medicare coverage